Full Press Release Details
Accessibility: Skip TopNav
Summit Therapeutics plc : Director/PDMR Shareholding
July 17, 2018 02:00 ET
Summit Therapeutics plc
Summit Therapeutics plc
Summit Therapeutics plc
("Summit" or the "Company")
Director / PDMR Share Dealing
Oxford, UK, Cambridge, MA, US, 17 July 2018 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces that it was notified on 16 July 2018 that Dr Frank Armstrong, Summit's Non-Executive Chairman, purchased 25,000 ordinary shares of 1p each in the Company at 39.5 pence per share.
Following this purchase, his shareholding in the Company has increased to 39,442 ordinary shares, representing approximately 0.05% of the Company's issued share capital.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name | Frank Armstrong | |||
| 2 | Reason for the notification | ||||
| a) | Position / status | Non-Executive Chairman | |||
| b) | Initial notification / Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Summit Therapeutics plc | |||
| b) | LEI | 213800NRW8AOMYMTBD89 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 1 pence each | |||
| Identification code | GB00BN40HZ01 | ||||
| b) | Nature of the transactions | Purchase of ordinary shares | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| 39.5 pence | 25,000 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | |||||
| - Price | |||||
| e) | Date of the transaction | 16 July 2018 | |||
| f) | Place of the transaction | London Stock Exchange |
About Summit Therapeutics
For more information, please contact:
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson |